Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .
Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder
BACKGROUND Treatment adherence is a significant problem in patients with bipolar disorder . This study was design ed to determine the efficacy of risperidone long-acting injectable ( LAI ) in the maintenance treatment of bipolar I disorder . METHODS Eligible patients with current or recent manic or mixed episodes ( n = 559 , aged 18 - 65 years ) were treated with open-label oral risperidone for 3 weeks ( period II ) and open-label risperidone LAI for 26 weeks ( n = 501 ; period III ) . Patients who maintained response ( n = 303 ) were r and omly allocated 1:1 to placebo injections ( n = 149 ) or to continue risperidone LAI ( n = 154 ) for up to 24 months ( period IV ) . RESULTS Most ( 77 % ) patients on risperidone LAI received a dose of 25 mg every 2 weeks during period IV . Time to recurrence for any mood episode ( primary outcome variable ) was significantly longer in the risperidone LAI group versus placebo ( p < .001 ) ; the difference was significant for time to recurrence of elevated-mood episode ( p < .001 ) but not time to recurrence of depressive episode ( p = .805 ) . Weight gains > or = 7 % ( compared with the period 's baseline ) occurred in 15 % of patients in period III ; in 12 % of patients on risperidone LAI and 3 % of patients on placebo in period IV . CONCLUSIONS Risperidone LAI monotherapy significantly delayed the time to recurrence of mood episodes , versus placebo , in this controlled , r and omized study in patients with bipolar I disorder . Risperidone LAI was tolerable and no new safety concerns emerged compared with previous studies of risperidone LAI
Risperidone long-acting injectable was found to be effective in protecting from any mood/manic symptom compared to placebo , but not from depressive recurrences .
Add-on or monotherapy paliperidone palmitate in SAD patients  protected from psychotic , depressive , and manic symptoms .
In patients with BD-I with a manic episode at study enrolment , aripiprazole monohydrate significantly delayed time to recurrence of manic episodes without inducing depressive episodes .
LAIs  are effective and well-tolerated maintenance treatments for BD and SAD .
They showed better efficacy in preventing mania than depression .
LAIs may be first-line for BD-I and SAD patients with a manic predominant polarity and with non-adherence problems
Long-Acting Injectable Antipsychotics ( LAIs ) are used to overcome non-compliance in psychoses , mainly schizophrenia spectrum disorders .
We aim ed to summarize available evidence of studies comparing the efficacy of LAIs to placebo or oral medications for Bipolar Disorder ( BD ) and /or Schizoaffective Disorder ( SAD ) .